title: Role of angiotensin II type 2 receptor during regression of cardiac hypertrophy in spontaneously hypertensive rats.
abstract: We previously reported that the AT1 receptor antagonist valsartan and the angiotensin converting enzyme (ACE) inhibitor enalapril decrease DNA synthesis and stimulate apoptosis in interstitial fibroblasts and epicardial mesothelial cells during regression of ventricular hypertrophy in spontaneously hypertensive rats (SHR). To examine the role of the AT2 receptor in this model, we studied hearts from SHR treated with valsartan or enalapril either alone or combined with the AT2 antagonist PD123319 for 1 or 2 weeks. Apoptosis was evaluated by quantification of DNA fragmentation or by TUNEL labeling. At 1 week, valsartan significantly increased ventricular DNA fragmentation, increased apoptosis in epicardial mesothelial cells, and decreased DNA synthesis. At 2 weeks, ventricular DNA content and cardiomyocyte cross-sectional area were significantly reduced. These valsartan-induced changes were attenuated by PD123319 co-administration. However, valsartan-induced increases in apoptosis of left ventricular interstitial non-cardiomyocytes was unaffected by the AT2 blocker. Enalapril-induced changes were similar to those observed with valsartan but were not affected by co-treatment with PD123319. These results demonstrate that AT1 and AT2 receptors act in a coordinated yet cell-specific manner to regulate cell growth and apoptosis in the left ventricle of SHR during AT1 receptor blockade but not ACE inhibition.
authors: Department of Pharmacology, Université de Montréal, Montreal, Quebec, Canada.
authors: Shant
authors: S
authors: Der Sarkissian
authors: Bun-Seng
authors: BS
authors: Tea
authors: Rhian M
authors: RM
authors: Touyz
authors: Denis
authors: D
authors: deBlois
authors: Taben M
authors: TM
authors: Hale
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D006332:Cardiomegaly / Q000188:drug therapy*; D053938:DNA Fragmentation / Q000187:drug effects; D004656:Enalapril / Q000494:pharmacology*; D007093:Imidazoles / Q000494:pharmacology*; D020287:In Situ Nick-End Labeling; D008297:Male; D010784:Photomicrography; D011725:Pyridines / Q000494:pharmacology*; D011897:Random Allocation; D051381:Rats; D011918:Rats, Inbred SHR; D044139:Receptor, Angiotensin, Type 2 / Q000502:physiology*; D013777:Tetrazoles / Q000494:pharmacology*; D014633:Valine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000068756:Valsartan
chemical_list: D007093:Imidazoles; D011725:Pyridines; D044139:Receptor, Angiotensin, Type 2; D013777:Tetrazoles; C073402:PD 123319; D004656:Enalapril; D000068756:Valsartan; D014633:Valine